# A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Study · id `cardio:ct-nct05936151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05936151](<https://clinicaltrials.gov/study/NCT05936151>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05936151

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

## Technical summary

Registry record NCT05936151. Randomized; double masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-10-01 (actual). Results posted on 2026-11-09.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 146 participants (enrolled count; ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Started: 2023-07-20 (actual) (ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2025-10-01 (actual) (ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Completion: 2025-10-21 (actual) (ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Results first posted: 2026-11-09 (ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Countries: United States; Canada; Italy; Spain; United Kingdom (ClinicalTrials.gov record NCT05936151, source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05936151-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Condition: Overweight or Obesity
- Condition: CKD
- Condition: Type 2 Diabetes
- Intervention (Drug): Retatrutide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 69505d3ae5763a6478f80c5c017fd1adbd4d28531fc3cf5dee964f3eecf83a54
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
